Conversely, individuals at moderate to severe risk of OSA with concurrent COVID-19 showed reduced levels of serum IL-6, Eotaxin-1/CCL11, and salivary MIP-3α/CCL20 compared to those with mild OSA risk and concurrent COVID-19. This evidence concerns the gene CCL20 and COVID-19.